pimavanserin
pimavanserin: sourced relationships with 1 company · 23 clinical trials tracked · 2 FDA decisions.
pimavanserin evidence translation
What we can confirm
2 FDA records · 23 tracked trials
What it means
What to watch
Prepared research question
How could pimavanserin → ACAD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | Approved |
| ACADIA PHARMACEUTICALS INC (ACAD) Reported 2016-04-29 · Current development: unknownSource Parkinson Disease; Adjunctive Treatment of Major Depressive … | Phase 4 |
| ACADIA PHARMACEUTICALS INC (ACAD) Reported 2016-04-29 · Current development: unknownSource Parkinson's Disease Psychosis; Alzheimer's Disease Psychosis | Phase 4 |
Clinical Trial Registry Records (23)showing 10 most recent
Effect of Pimavanserin on Aggression and Social Cognition.
Primary endpoint: Aggressive Responding on the Taylor Aggression Paradigm (TAP)
Does Pimavanserin (Nuplazid) Improve Sleep in Patients With Parkinson Disease Psychosis? A Pilot Study
Primary endpoint: Effect of pimavanserin on sleep fragmentation
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Primary endpoint: Change in 5HT2A receptor density measured using the PET radioligand MH.MZ
Open-label Pimavanserin 34mg at Bedtime for 6 Weeks for Insomnia in Veterans With Post-traumatic Stress Disorder: Proof of Concept Study
Primary endpoint: Recruitment rates
A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD)
Primary endpoint: Treatment-emergent Adverse Events
CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)
Primary endpoint: CGI-I Psychosis
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Primary endpoint: Change From Baseline at Week 6 in Caregiver-rated Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Primary endpoint: Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26
A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
Primary endpoint: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score
A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
Primary endpoint: Treatment-emergent Adverse Events (TEAEs)
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with pimavanserin?
pimavanserin has dated SEC/FDA relationship records for ACADIA PHARMACEUTICALS INC.
How many clinical trials involve pimavanserin?
BioSniper tracks 23 clinical trials involving pimavanserin.
What is pimavanserin's latest FDA decision?
The most recent tracked FDA decision for pimavanserin is Approval for 1 INDICATIONS AND USAGE NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [ see Clinical Studies (14) ] . NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ( 1 ), dated June 28, 2018.